Articolo in rivista, 2010, ENG

Inhibition of 3-hydroxy-3-methylglutaryl-coenzyme A reductase activity and of Ras farnesylation mediate antitumor effects of anandamide in human breast cancer cells.

Laezza C; Malfitano A; Proto MC; Esposito I; Gazzerro P; Formisano P; Pisanti S; Santoro A; Caruso MG; Bifulco M.

CNR, Inst Endocrinol & Expt Oncol, I-80131 Naples, Italy Univ Naples Federico 2, Dept Biol & Cellular, I-80131 Naples, Italy Univ Salerno, Dept Pharmaceut Sci, I-84084 Salerno, Italy Natl Inst Digest Dis, I-70013 Bari, Italy

The endocannabinoid system regulates cell proliferation in human breast cancer cells. Recently, we described that a metabolically stable anandamide analog, 2-methyl-2'-F-anandamide, by activation of CB1 receptors significantly inhibited cell proliferation of human breast cancer cell lines. In this study, we observed that the activation of the CB1 receptor, in two human mammary carcinoma cell lines, MDA-MB-231 and MCF7, caused the inhibition of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase activity due to a reduction of HMG-CoA reductase transcript levels. The decrease of HMG-CoA reductase activity induced the inhibition of the prenylation of proteins, in particular of the farnesylation of Ras oncogenic protein involved in cell proliferation of these cell lines. We suggest that the inhibitory effect of anandamide analog on tumor cell proliferation could be related to the inhibition of Ras farnesylation.

Endocrine-related cancer 18 , pp. 495–503

Keywords

CNR authors

Laezza Chiara

CNR institutes

IEOS – Istituto per l'endocrinologia e l'oncologia "Gaetano Salvatore"

ID: 21321

Year: 2010

Type: Articolo in rivista

Creation: 2010-12-07 00:00:00.000

Last update: 2015-11-19 15:25:45.000

CNR authors

External links

OAI-PMH: Dublin Core

OAI-PMH: Mods

OAI-PMH: RDF

External IDs

CNR OAI-PMH: oai:it.cnr:prodotti:21321

ISI Web of Science (WOS): 000279341700020